8-K: NeuroPace Q1 2026 Earnings: Revenue Up, Guidance Raised

NeuroPace reported first quarter 2026 financial results, with total revenue reaching $22.1 million and full-year revenue guidance increased to $99-$101 million.

Summary

• NeuroPace announced its financial results for the first quarter ended March 31, 2026.
• Total revenue for the quarter was $22.1 million, with core RNS System revenue at $21.7 million, showing a 19.5% year-over-year growth.
• Excluding DIXI Medical, non-GAAP revenue was $22.0 million, a 20.1% year-over-year increase.
• The company raised its full-year 2026 revenue guidance to $99 million - $101 million, up from $98 million - $100 million previously.
• This updated guidance assumes 21% to 23% growth in core RNS revenue from existing indications, excluding potential contributions from the idiopathic generalized epilepsy (IGE) indication expansion.
• GAAP net loss for the quarter was ($6.7) million, a slight increase from ($6.6) million in Q1 2025.
• Adjusted EBITDA loss, excluding DIXI Medical, improved to ($3.3) million from ($4.1) million in Q1 2025.
• NeuroPace completed the FDA mid-cycle review for the NAUTILUS PMA supplement, consistent with the expected regulatory timeline.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth exceeding expectations and guidance being raised, despite a continued net loss.

Positives

• Total revenue of $22.1 million for Q1 2026.
• Non-GAAP revenue (excluding DIXI Medical) grew 20.1% year-over-year to $22.0 million.
• RNS System revenue grew 19.5% year-over-year to $21.7 million.
• Full-year 2026 revenue guidance was raised to $99 million - $101 million.
• The company expects 21% to 23% growth in core RNS revenue for the full year.
• Adjusted EBITDA loss improved by $0.8 million year-over-year to ($3.3) million.
• Reached new all-time highs in active prescribers, accounts, and patient pipeline.
• Completed the FDA mid-cycle review for the NAUTILUS PMA supplement on schedule.

Negatives

• GAAP net loss increased slightly to ($6.7) million in Q1 2026 from ($6.6) million in Q1 2025.
• Non-GAAP gross margin decreased slightly to 82.5% from 83.6% in Q1 2025, due to a one-time inventory revaluation benefit in the prior year.
• Cash, cash equivalents, short-term investments, and restricted cash decreased to $54.8 million from $61.2 million at the end of the prior quarter.
• Long-term borrowings remain substantial at $59.0 million.

Risks

• Uncertainties related to market acceptance and adoption of NeuroPace's RNS System.
• Risks that operating expenses could be higher than anticipated, leading to faster cash resource depletion.
• Potential for lower than forecast gross margins.
• Risks related to the pricing of the RNS System and availability of adequate reimbursement.
• Risks related to regulatory compliance and expectations for regulatory approvals, including the NAUTILUS submission for IGE indication expansion.
• Risks related to product development, including AI-powered software and the next-generation device platform.
• Reliance on contractors and third-party suppliers.

Future Outlook

The company raised its full-year 2026 revenue guidance to $99 million to $101 million, projecting 21% to 23% growth in core RNS revenue from existing indications. They continue to expect potential contribution from the idiopathic generalized epilepsy (IGE) indication expansion following possible NAUTILUS PMA-Supplement approval in mid-2026. Full-year non-GAAP gross margin is expected between 81.5% and 82.5%, with non-GAAP operating expenses between $90 million and $92 million. Adjusted EBITDA is projected to be between ($8.5) million and ($9.5) million.

Management Comments

• "First quarter results reflect continued execution against the strategic priorities we outlined earlier this year," said Joel Becker, Chief Executive Officer of NeuroPace.
• "We remain focused on driving disciplined growth in our core RNS business, advancing our product roadmap, and progressing toward potential indication expansion, all while strengthening the operational foundation of the Company."
• "We continue to progress NAUTILUS through the regulatory review process and remain encouraged by the totality of the dataset supporting the IGE indication expansion."

Industry Context

StockSavvy.ai notes that NeuroPace's performance in Q1 2026, particularly the revenue growth and raised guidance, aligns with positive trends in the neuro-stimulation and epilepsy treatment device market, driven by increasing adoption of advanced therapies for drug-resistant conditions.

Comparison to Industry Standards

• The reported 20.1% year-over-year revenue growth for Q1 2026 is strong compared to the typical growth rates seen in the broader medical device sector, which often range from 5-15%.
• The non-GAAP gross margin of 82.5% is robust and competitive within the specialized medical device industry, indicating efficient manufacturing and pricing power.
• The company's focus on expanding indications for its RNS System mirrors industry trends towards personalized medicine and addressing unmet needs in chronic neurological disorders.

Stakeholder Impact

• Shareholders: Potential for increased value due to raised revenue guidance and positive operational improvements.
• Patients: Continued access to and potential expansion of treatment options for epilepsy.
• Healthcare Providers: Ongoing support and potential for expanded indications for the RNS System.
• Employees: Continued focus on operational scaling and product development.

Next Steps

• Continue to drive disciplined growth in the core RNS business.
• Advance the product roadmap.
• Progress toward potential indication expansion for the RNS System.
• Strengthen the operational foundation of the Company.
• Await potential NAUTILUS PMA-Supplement approval in mid-2026 for IGE indication expansion.
• Report DIXI Medical related operating results as discontinued operations beginning with Q2 2026.

Key Dates

Recommendation

The company is showing positive revenue growth and has raised its guidance, indicating solid execution. However, it continues to operate at a net loss, and the path to profitability requires sustained growth and careful expense management. The upcoming FDA decision on IGE indication expansion is a key catalyst. Therefore, a 'hold' recommendation is appropriate, pending further clarity on regulatory approvals and sustained financial performance.

Keywords

NeuroPace, 8-K, Q1 2026 Earnings, RNS System, Epilepsy Treatment, Medical Device, Revenue Guidance, FDA Approval